Home HOME Neoplasma 2013 Neoplasma Vol.60, No.5, p.576-583, 2013

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.60, No.5, p.576-583, 2013

Title: The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients ≥50 years from the Czech acute leukaemia clinical register (alert)
Author: P. Jindra, J. Muzik, K. Indrak, P. Zak, F. A. Sabty, T. Kozak, P. Cetkovsky, V. Koza,M. Karas, L. Raida, T. Szotkowski


Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients.

In the multicentre retrospective study we analyzed 96 consecutive AML patients ≥ 50 years allografted with related (n=59) or unrelated (n=37) donor.

The 2- year OS and DFS rates were 45 % and 42 % for the whole group.

The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896).

The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts.

Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011).

Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS.

In conclusion, our analysis indicates that outcomes of allografted AML patients aged ≥ 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor.

Keywords: AML, allogeneic HSCT, age, donor
Published online: 24-Jun-2013
Year: 2013, Volume: 60, Issue: 5 Page From: 576, Page To: 583

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.